A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1192-1198

  Justice, Glen ^a   Kessler, J F ^b   Jadeja, J ^c   Campos, L ^d   Weick, J ^e   Chen, C F ^f   Heatherington, A C ^f   Amado, R G ^f  

^a Pacific Coast Hematology/Oncology Medical Group   (United States)

^b Virginia Oncology Associates   (United States)

^c Hematology Oncology Associates of Jacksonville   (United States)

^d Oncology Consultants   (United States)

^e Hematology Oncology Associates   (United States)

^f AMGEN INC   (United States)

Author keywords

Anemia; Darbepoetin alfa; Drug administration schedule; Erythropoietin; Hemoglobin

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 25444502298     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi218     Document Type: Article

References (25)

1. Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Semin Hematol 1997; 34: 4-12.
2. Cella D, Bron D. The effect of epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 1999; 7: 177-182.
3. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000; 37: 14-17.
4. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In Murphy MJJ (ed.): Blood Cell Growth Factors: Their Present and Future use in Hematology and Oncology. Proceedings of the Beijing Symposium. Dayton, OH: AlphaMed Press 1991; 121-141.
5. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cane Inst 2002; 94: 1211-1220.
6. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
7. Egrie JC, Dwyer E, Browne JK et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-299.
8. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 2001; 84: 11-16.
9. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395.
10. Glaspy JA, Jadeja IS, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268-276.
11. Kotasek D, Steger G, Faught W et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39: 2026-2034.
12. Kaufman J, Reda D, Fye C et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-583.
13. Albitar S, Meulders Q, Hammoud H et al. Subcutaneous compared with intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 40-43.
14. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369.
15. Vanrenterghem Y, Bárány P, Mann JFE et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175.
16. Aranesp® (darbepoetin alfa) Prescribing Information. Breda, The Netherlands: Amgen Europe B.V. 2001.
17. NCCN. Clinical Practice Guidelines in Oncology, version 1. Jenkin-town, PA: National Comprehensive Cancer Network 2003.
18. Littlewood TJ, Bajetta E, Nortier JWR et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
19. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-4107.
20. Henke M, Guttenberger R, Barke A et al. Erythropoietin for patients undergoing radiotherapy: A pilot study. Radiother Oncol 1999; 50: 185-190.
21. Wurnig C, Windhager R, Schwameis E et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36: 155-159.
22. Porter JC, Leahey A, Polise K et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial. J Pediatr 1996; 129: 656-660.
23. Platanias LC, Miller CB, Mick R et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9: 2021-2026.
24. Glaspy J, Henry D, Patel R et al. A randomized trial evaluating the pharmacologic and hematologic effects of the timing of darbepoetin alfa and chemotherapy administration. Blood 2003; 102: 9b (Abstr 3737).
25. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416.